Advertisement

Cytomegalovirus Infection in Marrow Transplantation

  • Michael Boeckh
  • Raleigh Bowden
Part of the Cancer Treatment and Research book series (CTAR, volume 76)

Abstract

Historically, cytomegalovirus (CMV) disease has been the leading infectious cause of death after allogeneic marrow transplantation [1], Considerable progress has been made in understanding the immunology, development of diagnostic techniques, and prevention of CMV infection and disease after marrow transplantation. Recent advances made in prevention of CMV disease include the availability of antiviral agents as well as prevention of transfusion-acquired infection. This has led to a significant reduction of CMV disease after allogeneic marrow transplantation in both seropositive and seronegative patients. By contrast, continuing challenges include the treatment of CMV disease, particularly CMV pneumonia, and the prevention of CMV disease in seropositive autograft recipients in whom the risk of CMV infection is lower than in allograft recipients but the outcome is as severe.

Keywords

Graft Versus Host Disease Cytomegalovirus Infection Bone Marrow Transplant Recipient Acute Graft Versus Host Disease Antigenemia Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Meyers JD: Infections in marrow transplant recipients. In Mandell GL, Douglas RG Jr, Bennett JE (eds): Principles and Practices of Infectious Diseases. New York: Churchill Livingstone, 1990, pp 2291–2294.Google Scholar
  2. 2.
    Mach M, Stamminger T, Jahn G: Human cytomegalovirus: Recent aspects from molecular biology. J Gen Virol 70:3117–3146, 1989.PubMedGoogle Scholar
  3. 3.
    Mocarski ES Jr: Cytomegalovirus biology and replication. In The Human Herpesviruses Roizman B, Whitley RJ, Lopez C (eds): New York: Raven Press, 1993, pp 173–193.Google Scholar
  4. 4.
    Meyers JD, Flournoy N, Thomas ED: Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478–488, 1986.PubMedGoogle Scholar
  5. 5.
    Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A, Haake R, McGlave P, Ramsay N, Kersey J: Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease. Blood 67:1162–1167, 1986.PubMedGoogle Scholar
  6. 6.
    Wingard JR, Chen DY-H, Burns WH, Fuller DJ, Braine HG, Yeager AM, Kaiser H, Burke PJ, Graham ML, Santos GW, Sarai R: Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 71:1432–1437, 1988.PubMedGoogle Scholar
  7. 7.
    Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R: The effect of granulocyte transfusions upon the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 96:149–152, 1982.PubMedGoogle Scholar
  8. 8.
    Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006–1010, 1986.PubMedGoogle Scholar
  9. 9.
    Bowden RA, Sayers M, Gleaves CA, Banaji M, Newton B, Meyers JD: Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation: Considerations for blood banks. Transfusion 27:478–481, 1987.PubMedGoogle Scholar
  10. 10.
    Miller WJ, McCullough J, Balfour HH Jr, Haake RJ, Ramsay NKC, Goldman A, Bowman R, Kersey J: Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant 7:227–234, 1991.PubMedGoogle Scholar
  11. 11.
    Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD: Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164:483–487, 1991.PubMedGoogle Scholar
  12. 12.
    Enright H, Haake R, Weisdorf D, Ramsay N, McGlave P, Kersey J, Thomas W, McKenzie D, Miller W: Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation 55:1339–1346, 1993.PubMedGoogle Scholar
  13. 13.
    Webster A, Blizzard B, Pillay D, Prentice HG, Pothecary K, Griffiths PD: Value of routine surveillance cultures for detection of CMV pneumonitis following bone marrow transplantation. Bone Marrow Transplant 12:477–481, 1993.PubMedGoogle Scholar
  14. 14.
    Meyers JD, Ljungman P, Fisher LD: Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia. J Infect Dis 162:373–380, 1990.PubMedGoogle Scholar
  15. 15.
    De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van Der Meer JWW, Kunst VAJM: Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomega-lovirus-unscreened blood-bank donors. Transplantation 50:964–968, 1990.PubMedGoogle Scholar
  16. 16.
    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324:1005–1011, 1991.PubMedGoogle Scholar
  17. 17.
    Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601–1607, 1991.PubMedGoogle Scholar
  18. 18.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178, 1993.PubMedGoogle Scholar
  19. 19.
    Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 118:179–184, 1993.PubMedGoogle Scholar
  20. 20.
    Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Ranada JMF, Mandelli F, Kho P, Kennedy L, Bell AR for the European Acyclovir for CMV Prophylaxis Study Group: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 343:749–753, 1994.PubMedGoogle Scholar
  21. 21.
    Winston DJ, Gale RP: Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 8:7–11, 1991.PubMedGoogle Scholar
  22. 22.
    Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287–298, 1994.PubMedGoogle Scholar
  23. 23.
    Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HEM, Kolb H-J, Hartz AJ, Rimm AA: Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 104: 168–175, 1986.PubMedGoogle Scholar
  24. 24.
    Ljungman P, Aschan J, Azinge JN, Brandt L, Ehrnst A, Hammarström V, Klaesson S, Linde A, Lönnqvist B, Ringdén O, Wahren B, Gahrton G: Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 83:118–124, 1993.PubMedGoogle Scholar
  25. 25.
    Meyers JD, Flournoy N, Thomas ED: Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years’ experience. Rev Infect Dis 4:1119–1132, 1982.PubMedGoogle Scholar
  26. 26.
    Meyers JD: Prevention of cytomegalovirus infection after marrow transplantation. Rev Infect Dis 11(Suppl 7):S1691–S1705, 1989.PubMedGoogle Scholar
  27. 27.
    Winston DJ, Ho WG, Champlin RE: Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 12(Suppl 7):S776–792, 1990.PubMedGoogle Scholar
  28. 28.
    Horak DA, Schmidt GM, Zaia JA, Niland JC, Ahn C, Forman SJ: Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. Chest 102:1484–1490, 1992.PubMedGoogle Scholar
  29. 29.
    Crawford SW, Fisher L: Predictive value of pulmonary function tests before marrowtransplantation. Chest 101:1257–1264, 1992.PubMedGoogle Scholar
  30. 30.
    Ljungman P, Niederwieser D, Pepe MS, Longton G, Storb R, Meyers JD: Cytomegalo-virus infection after marrow transplantation for aplastic anemia. Bone Marrow Transplant 6:295–300, 1990.PubMedGoogle Scholar
  31. 31.
    Grob JP, Prentice HG, Hoffbrand AV, Tate T, Grundy JE, Griffiths PD, Hughes MD, Wimperis JZ, Brenner MK: Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1:774–776, 1987.PubMedGoogle Scholar
  32. 32.
    Meyers JD, Bowden RA, Shepp DH, Reed EC, Dandliker PS: Prevention of cytomegalovirus infection after marrow transplantation. In Gale RP (ed): Bone Marrow Transplantion: Current Controversies. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 91. New York: Alan R. Liss, 1989, pp 553–572.Google Scholar
  33. 33.
    Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD: Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80:1358–1364, 1992.PubMedGoogle Scholar
  34. 34.
    Schmidt CA, Oettle H, Wilborn F, Jessen J, Timm H, Schwerdtfeger R, Oertel J, Siegert W: Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant 13:71–75, 1994.PubMedGoogle Scholar
  35. 35.
    Wolf DG, Spector SA: Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 56:330–334, 1993.PubMedGoogle Scholar
  36. 36.
    Slavin MA, Gooley TA, Bowden RA: Prediction of cytomegalovirus pneumonia after marrow transplant from cellular characteristics and cytomegalovirus culture of bronchoal-veolar lavage fluid. Transplantation 58:915–919, 1994.PubMedGoogle Scholar
  37. 37.
    Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F, Vallbracht A, Schmidt H, Waller HD, Müller CA: Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 82: 1672–1678, 1993.PubMedGoogle Scholar
  38. 38.
    Fries BC, Khaira D, Pepe MS, Torok-Storb B: Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients. Exp Hematol 21:1387–1392, 1993.PubMedGoogle Scholar
  39. 38a.
    Boeckh M, Myerson D, Bowden RA: Early detection and treatment of cytomegalovirus infections in marrow transplant — Methodological aspects and implications for therapeutic interventions. Bone Marrow Transplant 14:S66–S70, 1994.PubMedGoogle Scholar
  40. 39.
    Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD: Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment. Blood 75:1888–1894, 1990.PubMedGoogle Scholar
  41. 40.
    Ljungman P, Björkstrand B, Ehrnst A, Forsgren M, Lönnqvist B: CMV infections after autologous bone marrow transplantation (ABMT). In Landini MP (ed): Progress in Cytomegalovirus Research. Exerpta Medica Congress Series 978: Elsevier Science, 1991, pp 15–18.Google Scholar
  42. 40a.
    Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA: High-dose acyclovir for prevention of cytomegalovirus disease after autologous marrow transplant. J Infect Dis, in press.Google Scholar
  43. 41.
    Appelbaum FR, Meyers JD, Fefer A, Flournoy N, Cheever MA, Greenberg PD, Hackman R, Thomas ED: Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation 33:265–268, 1982.Google Scholar
  44. 42.
    Fest T, Angonin R, Mougin C, Deschaseaux M, Lab M, Cahn JY, Hervé P: Detection of cytomegalovirus-infected cells in bone marrow biopsy specimens obtained before allogeneic bone marrow transplantation from donors and recipients. Transplantation 57:1681–1683, 1994.PubMedGoogle Scholar
  45. 43.
    Rice GPA, Schrier RD, Oldstone MBA: Cytomegalovirus infects human lymphocytes and monocytes: Virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 81:6134–6138, 1984.PubMedGoogle Scholar
  46. 44.
    Einhorn L, Öst Å: Cytomegalovirus infection of human blood cells. J infect Dis 149:207–214, 1984.PubMedGoogle Scholar
  47. 45.
    Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH: Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72:2059–2064, 1991.PubMedGoogle Scholar
  48. 46.
    Söderberg C, Larsson S, Bergstedt-Lindqvist S, Müler E: Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol 67:3166–3175, 1993.PubMedGoogle Scholar
  49. 47.
    Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson JA: Human cytomegalovirus productively infects primary differentiated macrophages. J Virol 65:6581–6588, 1991.PubMedGoogle Scholar
  50. 48.
    Winston DJ, Huang E-S, Miller MJ, Lin C-H, Winston GH, Gale RP, Champlin RE: Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med 102:16–20, 1985.PubMedGoogle Scholar
  51. 49.
    Fries BC, Chou S, Boeckh M, Torok-Storb B: Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis 169:769–774, 1994.PubMedGoogle Scholar
  52. 50.
    Boland JG, Vlieger AM, Ververs C, deGast GC: Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol 88:506–511, 1992.PubMedGoogle Scholar
  53. 51.
    Vanprooijen HC, Visser JJ, Vanoostendorp WR, Degast GCD, Verdonck LF: Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant receipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 87:144–147, 1994.Google Scholar
  54. 52.
    Meyers JD, Flournoy N, Thomas ED: Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 142:816–824, 1980.PubMedGoogle Scholar
  55. 53.
    Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Sarai R, Burns WH: Cytotoxic T cells in cytomegalovirus infection. N Engl J Med 307:7–13, 1982.PubMedGoogle Scholar
  56. 54.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380, 1991.PubMedGoogle Scholar
  57. 55.
    Drew WL: Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 14:608–615, 1992.PubMedGoogle Scholar
  58. 56.
    Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, Cordonnier C, Debusscher L, De Laurenzi A, Kolb HJ, Messina C, Newland AC, Prentice HG, Richard C, Ruutu T, Tilg H, Verdonck L: Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European bone marrow transplant group. Clin Infect Dis 14:831–835, 1992.PubMedGoogle Scholar
  59. 57.
    Meyers JD, Flournoy N, Wade JC, Hackman RC, McDougall JK, Neiman PE, Thomas ED: Biology of interstitial pneumonia after marrow transplantation. In Gale RP (ed): Recent Advances in Bone Marrow Transplantation. New York: Alan R. Liss, 1983, pp 405–423.Google Scholar
  60. 58.
    Winston DJ, Territo MC, Ho WG, Miller MJ, Gale RP, Golde DW: Alveolar macrophage dysfunction in human bone marrow transplant recipients. Am J Med 73:859–866, 1982.PubMedGoogle Scholar
  61. 59.
    Bowden RA, Dobbs S, Kopecky KJ, Crawford SW, Meyers JD: Increased cytotoxicity against cytomegalovirus-infected target cells by bronchoalveolar lavage cells from marrow transplant patients with cytomegalovirus pneumonia. J Infect Dis 158:773–779, 1988.PubMedGoogle Scholar
  62. 60.
    Grundy JE, Shanley JD, Griffiths PD: Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet 2:996–999, 1987.PubMedGoogle Scholar
  63. 61.
    Balthesen M, Messerle M, Reddehase MJ: Lungs are a major organ site of cytomega-virus latency and recurrence. J Virol 67:5360–5366, 1993.PubMedGoogle Scholar
  64. 62.
    Milburn HJ, Poulter LW, Prentice HG, du Bois RM: Pulmonary cell populations in recipients of bone marrow transplants with interstitial pneumonitis. Thorax 44:570–1575, 1989.PubMedGoogle Scholar
  65. 63.
    Leskinen R, Taskinen E, Volin L, Tukiainen P, Ruutu T, Hayry P: Use of bronchoalveolar lavage cytology and determination of protein contents in pulmonary complications of bone marrow transplant recipients. Bone Marrow Transplant 5:241–245, 1990.PubMedGoogle Scholar
  66. 64.
    Escudier E, Fleury J, Cordonnier C, Vernant JP, Bernaudin JF: Large granular lymphocytes in bronchoalveolar lavage fluids from immunocompromised patients with cytomegalovirus pneumonitis. Am J Clin Pathol 86:641–645, 1986.PubMedGoogle Scholar
  67. 65.
    Bowden RA, Mori M, Dobbs S, Hackman R, Kopecky K, Crawford S: Mononuclear cell reconstitution in the lung after marrow transplantation. Lack of influence of cytomegalo-virus pneumonia, irradiation, and graft-versus-host disease. Transplantation 55:557–561, 1993.PubMedGoogle Scholar
  68. 66.
    Slavin MA, Dobbs S, Crawford S, Bowden RA: Interleukin-2, interferon-gamma and natural killer cell activity in bronchoalveolar lavage fluid from marrow transplant recipients with cytomegalovirus pneumonia. Bone Marrow Transplant 11:113–118, 1993.PubMedGoogle Scholar
  69. 67.
    Slavin MA, Gleaves CA, Schoch HG, Bowden RA: Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplant by centrifugation culture. J Clin Microbiol 30:2776–2779, 1992.PubMedGoogle Scholar
  70. 68.
    Ruutu P, Ruutu T, Volin L, Tukiainen P, Ukkonen P, Hovi T: Cytomegalovirus is frequently isolated in bronchoalveolar lavage fluid of bone marrow transplant recipients without pneumonia. Ann Intern Med 112:913–916, 1990.PubMedGoogle Scholar
  71. 69.
    Chou, S: Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J Infect Dis 166:604–607, 1992.PubMedGoogle Scholar
  72. 70.
    Appleton AL, Sviland L: Pathogenesis of GVHD: role of herpes viruses. Bone Marrow Transplant 11:349–355, 1993.PubMedGoogle Scholar
  73. 71.
    Boström L, Ringdén O, Gratama JW, Jacobsen N, Zwaan F, Nilsson B for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation: The impact of pretransplant herpesvirus serology on acute and chronic graft-versus-host disease. Transplant Proc 22:206, 1990.PubMedGoogle Scholar
  74. 72.
    Gleaves CA, Smith TF, Shuster EA, Pearson GR: Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 19:917–919, 1984.PubMedGoogle Scholar
  75. 73.
    Gleaves CA, Reed EC, Hackman RC, Meyers JD: Rapid diagnosis of invasive cytome-galovirus infection by examination of tissue specimens in centrifugation culture. Am J Clin Pathol 88:354–358, 1987.PubMedGoogle Scholar
  76. 74.
    Hackman RC, Wolford JL, Gleaves CA, Myerson D, Beauchamp MD, Meyers JD, McDonald GB: Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. Transplantation 57:231–237, 1994.PubMedGoogle Scholar
  77. 75.
    Boeckh M, Gleaves CA, Bindra R, Meyers JD: Comparison of MRC-5 and U-373MG astrocytoma cells for detection of cytomegalovirus in shell vial centrifugation cultures. Eur J Clin Microbiol Infect Dis 10:569–572, 1991.PubMedGoogle Scholar
  78. 76.
    Crawford SE, Bowden RA, Hackman RC, Gleaves CA, Meyers JD, Clark JG: Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. An Intern Med 108:180–185, 1988.Google Scholar
  79. 77.
    Gleaves CA, Smith TF, Shuster EA, Pearson GR: Comparison of standard tube and shell vial culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 21:217–221, 1985.PubMedGoogle Scholar
  80. 78.
    Stirk PR, Griffiths PD: Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in cell culture. J Med Virol 21:329–337, 1987.PubMedGoogle Scholar
  81. 79.
    Griffiths PD, Panjwani DD, Stirk PR, Ball MG, Ganczakowski M, Backlock HA, Prentice HG: Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early fluoresent foci. Lancet 2:1242–1244, 1984.PubMedGoogle Scholar
  82. 80.
    Ashley R, Peterson E, Abbo H, Gold D, Corey L: Comparison of monoclonal antibodies for rapid detection of cytomegalovirus in spin-amplified plate cultures. J Clin Micribiol 27:2858–2860, 1989.Google Scholar
  83. 81.
    Leland DS, Hansing RL, French MLV: Clinical experience with cytomegalovirus isolation using conventional cell cultures and early antigen detection in centrifugation-enhanced shell vial cultures. J Clin Microbiol 27:1159–1162, 1989.PubMedGoogle Scholar
  84. 82.
    Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC: Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 320:289–314, 1989.PubMedGoogle Scholar
  85. 83.
    Landry ML, Ferguson D: Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol 31:2851–2856, 1993.PubMedGoogle Scholar
  86. 84.
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T: High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 120:375–381, 1994.PubMedGoogle Scholar
  87. 85.
    van der Bij W, Torensma R, van Son WJ, Anema J, Schirm J, Tegzess AM, The TH: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 25:179–188, 1988.PubMedGoogle Scholar
  88. 86.
    Revello MG, Percivalle E, Di Matteo A, Morini F, Gema G: Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol 73:437–442, 1992.PubMedGoogle Scholar
  89. 87.
    Grefte JMM, van der Gun BTF, Schmolke S, van der Giessen M, van Son WJ, Plachter B, Jahn G, The TH: The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 73:2923–2932, 1992.PubMedGoogle Scholar
  90. 88.
    Gerna G, Zipeto D, Percivalle E, Parea M, Revello MG, Maccario R, Peri G, Milanesi G: Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 166:1236–1244, 1992.PubMedGoogle Scholar
  91. 89.
    Gerna G, Revello MG, Percivalle E, Morini F: Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 30:1232–1237, 1992.PubMedGoogle Scholar
  92. 90.
    Boeckh M, Woogerd PM, Stevens-Ayers T, Ray CG, Bowden RA: Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol 32:832–834, 1994.PubMedGoogle Scholar
  93. 91.
    Erice A, Holm MA, Gill PC, Henry S, Dirksen CL, Dunn DL, Hillam RP, Balfour HH Jr: Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. J Clin Microbiol 30:2822–2825, 1992.PubMedGoogle Scholar
  94. 92.
    Bein G, Bitsch A, Hoyer J, Kirchner H: The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods 137:175–180, 1991.PubMedGoogle Scholar
  95. 93.
    Gerna G, Revello MG, Percivalle E, Zavattoni M, Parea M, Battaglia M: Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 28:2681–2688, 1990.PubMedGoogle Scholar
  96. 94.
    Niubò J, Pérez JL, Carvajal A, Ardanuy C, Martin R: Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay. J Clin Microbiol 32:1119–1120, 1994.PubMedGoogle Scholar
  97. 95.
    van den Berg AP, Klompmaker IJ, Haagsma EB, Scholten-Sampson A, Bijleveld, CMA, Schirm J, van der Giessen M, Slooff MJH, The TH: Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 164:265–270, 1991.PubMedGoogle Scholar
  98. 96.
    Sayer HG, Lington G, Bowden R, Pepe M, Storb R: Increased risk of infection in marrow transplant patients given methylprednisolone for graft-versus-host disease prevention. Blood 84:1328–1332, 1994.PubMedGoogle Scholar
  99. 97.
    Vlieger AM, Boland GJ, Jiwa NM, de Weger RA, Willemze R, de Gast GC, Falkenburg JHF: Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 9:247–253, 1992.PubMedGoogle Scholar
  100. 98.
    de Gast GC, Boland GJ, Vlieger AM, de Weger RA, Verdonck LF, Zwaan FE, Jiwa NM: Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 9:221–225, 1992.PubMedGoogle Scholar
  101. 99.
    The TH, ven der Ploeg M, van den Berg AP, Vlieger AM, ven der Giessen M, van Son WJ: Direct detection of cytomegalovirus in peripheral blood leukocytes — a review of the antigenemia assay and polymerase chain reaction. Transplantation 54:193–198, 1992.PubMedGoogle Scholar
  102. 100.
    van den Berg AP, van Son WJ, Haagsma EB, Klompmaker IJ, Tegzess AM, Schirm J, Dijkstra G, van der Giessen M, Slooff MJH, The TH: Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 55:847–851, 1993.PubMedGoogle Scholar
  103. 101.
    van den Berg AP, van den Bij W, van Son WJ, Anema J, van der Giessen M, Schirm J, Tegzess AM, The TH: Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation — A report of 130 consecutive patients. Transplantation 48:991–995, 1989.PubMedGoogle Scholar
  104. 102.
    Saltzman RL, Quirk MR, Jordan MC: High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest 90:1832–1838, 1992.PubMedGoogle Scholar
  105. 103.
    Gerna G, Zipeto D, Parea M, Revello MG, Suini E, Percivalle E, Zavattoni M, Grossi P, Milanesi G: Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant patients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 164:488–498, 1991.PubMedGoogle Scholar
  106. 104.
    The TH, van den Berg AP, van Son WJ, Klompmaker IJ, Harmsen MC, van der Giessen M: Monitoring for cytomegalovirus after organ transplantation: A clinical perspective. Transplant Proc 25:5–9, 1993.PubMedGoogle Scholar
  107. 105.
    Clinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist V-A, Zanchetta N, Monforte AD, Wahren B, Lazzarin A, Linde A: Cytomegalovirus infection of the central nervous system in patients with AIDS: Diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 166:1408–1411, 1992.Google Scholar
  108. 106.
    Gozlan J, Salord J-M, Roullet E, Baudrimont M, Caburet F, Picard O, Meyohas M-C, Duvivier C, Jacomet C, Petit J-C: Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 166:1416–1421, 1992.PubMedGoogle Scholar
  109. 107.
    Wolf DG, Spector SA: Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 166:1412–1415, 1992.PubMedGoogle Scholar
  110. 108.
    van Dorp WT, Vlieger A, Jiwa NM, van Es LA, van der Ploeg M, van Saase JLCM, van der Woude FJ: The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation. Transplantation 54:661–664, 1992.PubMedGoogle Scholar
  111. 109.
    Jiwa NM, van Gemert GW, Raap AK, van de Rijke FM, Mulder A, Lens PF, Salimans MM, Zwaan FE, van Dorp W, van der Ploeg M: Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 48:72–76, 1989.PubMedGoogle Scholar
  112. 110.
    Einsele H, Ehninger G, Steidle M, Vallbracht A, Müller M, Schmidt H, Saal JG, Waller HD, Müller CA: Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 338:1170–1172, 1991.PubMedGoogle Scholar
  113. 111.
    Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA: Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 77:1104–1110, 1991.PubMedGoogle Scholar
  114. 112.
    Brytting M, Xu W, Wahren B, Sundqvist V-A: Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 30:1937–1941, 1992.PubMedGoogle Scholar
  115. 113.
    Ishigaki S, Takeda M, Kura T, Ban N, Saitoh T, Sakamaki S, Watanabe N, Kohgo Y, Nitsu Y: Cytomegalovirus DNS in the sera of patients with cytomegalovirus pneumonia. Br J Haematol 79:198–204, 1991.PubMedGoogle Scholar
  116. 114.
    Spector SA, Merrill R, Wolf D, Dankner WM: Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 30:2359–2365, 1992.PubMedGoogle Scholar
  117. 115.
    Aspin MM, Gallez-Hawkins GM, Giugni TD, Tegtmeier B, Lang DI, Schmidt GM, Forman SJ, Zaia JA: Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients. J Clin Microbiol 32:2266–2269, 1994.PubMedGoogle Scholar
  118. 116.
    Cagle PT, Buffone G, Holland VA, Samo T, Demmler GJ, Noon GP, Lawrence EC: Semiquantitative measurement of cytomegalovirus DNA in lung and heart-lung transplant patients by in vitro DNA amplification. Chest 101:93–96, 1992.PubMedGoogle Scholar
  119. 117.
    Fox JC, Griffiths PD, Emery VC: Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 73:2405–2408, 1992.PubMedGoogle Scholar
  120. 118.
    Drouet E, Boibieux A, Michelson S, Ecochard R, Biron F, Peyramond D, Colimon R, Denoyel G: Polymerase chain reaction detection of cytomegalovirus DNA in peripheral blood leukocytes as a predictor of cytomegalovirus disease in HIV-infected patients. AIDS 7:665–668, 1993.PubMedGoogle Scholar
  121. 119.
    Bitsch A, Kirchner H, Dupke R, Bein G: Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis 167:740–743, 1993.PubMedGoogle Scholar
  122. 120.
    Gozlan J, Caburet F, Tancrede C, Petit J-C: A reverse polymerase chain reaction method for detection of human cytomegalovirus late transcripts in cells infected in vitro. J Virol Methods 40:1–10, 1992.PubMedGoogle Scholar
  123. 121.
    Cathomas G, Morris P, Pekle K, Cunningham I, Emanuel D: Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 81:1909–1914, 1993.PubMedGoogle Scholar
  124. 122.
    Myerson D, Lingenfelter PA, Gleaves CA, Meyers JD, Bowden RA: Diagnosis of cytomegalovirus pneumonia by the polymerase chain reaction with archived frozen lung tissue and bronchoalveolar lavage fluid. Am J Clin Pathol 100:407–413, 1993.PubMedGoogle Scholar
  125. 123.
    Eriksson BM, Brytting M, Zweygbergwirgart B, Hillerdal G, Oldingstenkvist E, Linde A: Diagnosis of cytomegalovirus in bronchoalveolar lavage by polymerase chain reaction, in comparison with virus isolation and detection of viral antigen. Scand J Infect Dis 25:421–427, 1993.PubMedGoogle Scholar
  126. 124.
    Jiwa M, Steenbergen RDM, Zwaan FE, Kluin PM, Raap AK, van der Ploeg M: Three sensitive methods for the detection of cytomegalovirus in lung tissue of patients with interstitial pneumonitis. Am J Clin Pathol 93:491–494, 1990.PubMedGoogle Scholar
  127. 125.
    Burgart LJ, Heller MJ, Reznicek MJ, Greiner TC, Teneyck CJ, Robinson RA: Cytomegalovirus detection in bone marrow transplant patients with idiopathic pneumonitis: A clinicopathologic study of the clinical utility of the polymerase chain reaction on open lung biopsy specimen tissue. Am J Clin Pathol 96:572–576, 1991.PubMedGoogle Scholar
  128. 126.
    Persons DL, Moore JA, Fishback JL: Comparison of polymerase chain reaction, DNA hybridization, and histology with viral culture to detect cytomegalovirus in immuno-suppressed patients. Mod Pathol 4:149–153, 1991.PubMedGoogle Scholar
  129. 127.
    Shibata M, Terashima M, Kimura H, Kuzushima K, Yoshida J, Horibe K, Morishima T: Quantitation of cytomegalovirus DNA in lung tissue of bone marrow transplant recipients. Hum Pathol 23:911–915, 1992.PubMedGoogle Scholar
  130. 128.
    Winston DJ, Ho WG, Lin C-H, Bartoni K, Budinger MD, Gale RP, Champlin RE: Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12–18, 1987.PubMedGoogle Scholar
  131. 129.
    Meyers JD, Spencer HC, Jr, Watts JC, Gregg MB, Stewart JA, Troupin RH, Thomas ED: Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 82:181–188, 1975.Google Scholar
  132. 130.
    Beschorner WE, Hutchins GM, Burns WH, Sarai R, Tutschka PJ, Santos GW: Cytomegalovirus pneumonia in bone marrow transplant recipients: Miliary and diffuse patterns. Am Rev Respir Dis 122:107–114, 1980.PubMedGoogle Scholar
  133. 131.
    Bower M, Barton SE, Nelson MR, Bobby J, Smith D, Youle M, Gazzard BG: The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. AIDS 4:317–320, 1990.PubMedGoogle Scholar
  134. 132.
    Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, Flournoy N, Kirk LE, Kersey JH, Thomas ED, Balfour HH. Jr: Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318:70–75, 1988.PubMedGoogle Scholar
  135. 133.
    Shepp DH, Dandliker PS, de Miranda P, Burnette TC, Cederberg DM, Kirk LE, Meyers JD: Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 103:368–373, 1985.PubMedGoogle Scholar
  136. 134.
    Winston DJ, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, Busuttil RW, Champlin RE: Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 10(Suppl 3): S547–S553, 1988.PubMedGoogle Scholar
  137. 135.
    Kraemer KG, Neiman PE, Reeves WC, Thomas ED: Prophylactic adenine arabinoside following marrow transplantation. Transplant Proc 10:237–240, 1978.PubMedGoogle Scholar
  138. 136.
    Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED: Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 141:555–562, 1980.PubMedGoogle Scholar
  139. 137.
    Meyers JD, McGuffin RW, Bryson YJ, Cantell K, Thomas ED: Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis 146:80–84, 1982.PubMedGoogle Scholar
  140. 138.
    Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD, Meyers JD: Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 73:249–256, 1982.PubMedGoogle Scholar
  141. 139.
    Meyers JD, Flournoy N, Sanders JE, McGuffin RW, Newton BA, Fisher LD, Lum LG, Appelbaum FR, Doney K, Sullivan KM, Storb R, Buckner CD, Thomas ED: Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107:809–816, 1987.PubMedGoogle Scholar
  142. 140.
    Erice A, Jordan C, Chace BA, Fletcher C, Chinnock BJ, Balfour HH, Jr: Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocom-promised hosts. JAMA 257:3082–3087, 1987.PubMedGoogle Scholar
  143. 141.
    Reed EC, Dandliker PS, Meyers JD: Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl] guanine and high-dose corticosteroids. Ann Intern Med 105:214–215, 1986.PubMedGoogle Scholar
  144. 142.
    Blacklock HA, Griffiths P, Stirk P, Prentice HG: Specific hyperimmune globulin for cytomegalovirus pneumonia [letter]. Lancet 2:152–153, 1985.PubMedGoogle Scholar
  145. 143.
    Reed EC, Bowden RA, Dandliker PS, Gleaves CA, Meyers JD: Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 156:641–645, 1987.PubMedGoogle Scholar
  146. 144.
    Wilson EJ, Medearis DN, Jr, Hansen LA, Rubin RH: 9-(1-3-Dihydroxy-2-propoxymethyl) guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother 31:1017–1020, 1987.PubMedGoogle Scholar
  147. 145.
    Shanley JD, Pesanti E: The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection J Infect Dis 151:454, 1985.PubMedGoogle Scholar
  148. 146.
    Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:783–788, 1988.PubMedGoogle Scholar
  149. 147.
    Schmidt GM, Kovacs A, Zaia JA, Horak DA, Blume KG, Nademanee AP, O’Donnell MR, Snyder DS, Forman SJ: Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46:905–907, 1988.PubMedGoogle Scholar
  150. 148.
    Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kerman NA, Laver J, Stover D, White DA, Fels A, Polsky B, Castro-Malaspina H, Peppard JR, Bartus P, Hammerling U, O’Reilly RJ: Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109:777–782, 1988.PubMedGoogle Scholar
  151. 149.
    Verdonck LF, de Gast GC, Dekker AW, de Weger RA, Schuurman H-J, Rozenberg-Arska M: Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 4:187–189, 1989.PubMedGoogle Scholar
  152. 150.
    Aulitzky WE, Tilg H, Niederwieser D, Hackl M, Meister B, Huber C: Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. J Infect Dis 158:488–489, 1988.PubMedGoogle Scholar
  153. 151.
    Aschan J, Ringden O, Ljungman P, Lonnqvist B, Ohlman S: Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 24:143–150, 1992.PubMedGoogle Scholar
  154. 152.
    Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, McDonald GB, Meyers JD: Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients: A randomized, placebo-controlled trial. Ann Intern Med 112:505–510, 1990.PubMedGoogle Scholar
  155. 153.
    Spencer GD, Hackman RC, McDonald GB, Amos DE, Cunningham BA, Meyers JD, Thomas ED: A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 42:602–607, 1986.PubMedGoogle Scholar
  156. 154.
    McDonald GB, Sharma P, Hackman RC, Meyers JD, Thomas ED: Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88: 1111–1117, 1985.PubMedGoogle Scholar
  157. 155.
    Razis E, Cook P, Mittelman A, Ahmed T: Treatment of gancyclovir resistant cytomegalovirus with foscarnet: A report of two cases occurring after bone marrow transplantation. Leuk Lymphoma 12:477–480, 1994.PubMedGoogle Scholar
  158. 156.
    Verdonck LF, van Heugten H, de Gast GC: Delay in platelet recovery after bone marrow transplantation: Impact of cytomegalovirus infection. Blood 66:921–925, 1985.PubMedGoogle Scholar
  159. 157.
    Simmons P, Kaushansky K, Torok-Storb B: Mechanisms of a cytomegalovirus-mediated myelosuppression: Perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA 87:1386–1390, 1990.PubMedGoogle Scholar
  160. 158.
    Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, St Jeor SC: Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 80:170–178, 1992.PubMedGoogle Scholar
  161. 159.
    MacKintosh RF, Adlish J, Hall SW, St Jeor S, Smith E, Tavossoli M, Zanjani ED (1993): Suppression of normal human hematopoiesis by cytomegalovirus in vitro. Exp Hematol 21:243–250, 1993.PubMedGoogle Scholar
  162. 160.
    Apperley JF, Dowding C, Hibbin J, Buiter J, Matutes E, Sissons PJ, Gordon M, Goldman JM: The effect of cytomegalovirus on hemopoiesis: In vitro evidence for selective infection of marrow stromal cells. Exp Hematol 17:38–45.Google Scholar
  163. 161.
    Sing GK, Ruscetti FW: Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood 75:1965–1973, 1990.PubMedGoogle Scholar
  164. 162.
    Ljungman P, Griffiths P: Definitions of cytomegalovirus infection and disease. In Michelsons (ed): Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Amsterdam: Elsevier Science, 1993 pp 233–237.Google Scholar
  165. 163.
    Bilgrami S, Almeida GD, Quinn JJ, Tuck D, Bergstrom S, Dainiak N, Poliquinn C, Ascensao JL: Pancytopenia in allogeneic marrow tranplant recipients: Role of cytomegalovirus. Br J Haematol 87:357–362, 1994.PubMedGoogle Scholar
  166. 164.
    Verdonck LF, de Graan-Hentzen YCE, Dekker AW, Mudde GC, de Gast GC: Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 2:73–78, 1987.PubMedGoogle Scholar
  167. 165.
    Bowden RA, Sayers MH, Cays M, Slichter SJ: The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant (abstr). Transfusion 29:205, 1989.Google Scholar
  168. 166.
    DeWitte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van Der Meer JWW: Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50:964–968, 1990.Google Scholar
  169. 167.
    Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD: Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246–250, 1991.PubMedGoogle Scholar
  170. 168.
    Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Clift RA, Hansen JA, Sanders JE, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712, 1990.PubMedGoogle Scholar
  171. 169.
    Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lönnqvist B, Ringdén O, Wahren B: Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1:185–192, 1986.PubMedGoogle Scholar
  172. 170.
    Schmidt GM: Prophylaxis of cytomegalovirus infection after bone marrow transplantation. Semin Oncol 19:20–26, 1992.PubMedGoogle Scholar
  173. 171.
    Bacigalupo A, Vanlint MT, Tedone E, Moro F, Sanna MA, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F, Lamparelli T, Marmont AM: Early treatment of CMV infections in allogeneic bone marrow transplant receipients with foscarnet or ganciclovir. Bone Marrow Transplant 13:753–758, 1994.PubMedGoogle Scholar
  174. 172.
    Atkinson K, Downs K, Golenia M, Biggs J, Marshall G, Dodds A, Concannon A: Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection. Br J Haematol 79:57–62, 1991.PubMedGoogle Scholar
  175. 173.
    Yau JC, Dimopoulos MA, Huan SD, Tarrand JJ, Spencer V, Spitzer G, Meneghetti CM, Wallerstein RO, Andersson BS, LeMaistre CF: Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplanation. Eur J Haematol 47:371–376, 1991.PubMedGoogle Scholar
  176. 174.
    von Bueltzingsloewen A, Bordigoni P, Witz F, Bene MC, Schmitt C, Lacour B, Sommelet D: Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 12:197–202, 1993.Google Scholar
  177. 175.
    Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, vanBesien K, Mehra R, Deisseroth AB, Andersson B, Luna M, Tarrand JJ, Champlin RE: Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 13:461–464, 1994.PubMedGoogle Scholar
  178. 176.
    Bowden RA, Digel J, Reed EC, Meyers JD: Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 156:899–903, 1987.PubMedGoogle Scholar
  179. 177.
    Li C-R, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of HLA-restricted bytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979, 1994.PubMedGoogle Scholar
  180. 178.
    Slavin MA, Bindra RR, Gleaves CA, Pettinger MB, Bowden RA: Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 37:1360–1363, 1993.PubMedGoogle Scholar
  181. 179.
    Reusser P, Gambertoglio JG, Lilleby K, Meyers JD: Phase I—II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 166:473–479, 1992.PubMedGoogle Scholar
  182. 180.
    Bacigalupo A, Tedone E, Vanlint MT, Trespi G, Lonngren M, Sanna MA, Moro F, Frassoni F, Occhini D, Gualandi F, Lamparelli T, Figari O, Benvenuto F, Raffo MR, Sogno G, Isaza A, Bernabo’DiNegro G, Felletti R, Hale G, Marmont AM: CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 13:783–788, 1994.PubMedGoogle Scholar
  183. 181.
    Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, Wright GG, Levin MJ, Thomas ED: Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 98:442–446, 1983.PubMedGoogle Scholar
  184. 182.
    Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN, Lin C, Gossett TG, Merigan TC, Gale RP: Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 97:11–18, 1982.PubMedGoogle Scholar
  185. 183.
    Kubanek B, Ernst P, Ostendorf P, Schäfer U, Wolf H: Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant Proc 17:468–469, 1985.Google Scholar
  186. 184.
    Condie RM, O’Reilly RJ: Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med 76(Suppl 3A): 134–141, 1984.PubMedGoogle Scholar
  187. 185.
    Ringden O, Pihlstedt P, Volin L, Nikoskelainen J, Lonnqvist B, Ruutu P, Ruutu T, Toivanen A, Wahren B: Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: A randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 2:299–305, 1987.PubMedGoogle Scholar
  188. 186.
    O’Reilly RJ, Reich L, Gold J, Kirkpatrick D, Dinsmore R, Kapoor N, Condie R: A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: Preliminary results. Transplant Proc 15:1405–1411, 1983.Google Scholar
  189. 187.
    Winston DJ, Ho, WG, Bartoni K, Champlin RE: Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283–288, 1993.PubMedGoogle Scholar
  190. 188.
    Bowden RA, Sullivan KM: Correspondence: Prophylaxis of cytomegalovirus disease in allogeneic bone marrow transplantation. J Infect Dis 165:972–973, 1992.Google Scholar
  191. 189.
    Messori A, Rampazzo R, Scroccaro G, Martini N: Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation — A meta-analysis. Bone Marrow Transplant 13:163–167, 1994.PubMedGoogle Scholar
  192. 190.
    Guglielmo JB, Wong-Beringer A, Linker CA: Immune globulin therapy in allogeneic bone marrow transplant: A critical review. Bone Marrow Transplant 13:499–510, 1994.PubMedGoogle Scholar
  193. 191.
    Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR: Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 12:273–282, 1993.PubMedGoogle Scholar
  194. 192.
    Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP: High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy — A study of the American-bone-marrow-transplant-group. Ann Intern Med 118:937–942, 1993.PubMedGoogle Scholar
  195. 193.
    Aulitzky WE, Schulz TF, Tilg H, Niederwieser D, Larcher K, Ostberg L, Scriba M, Martindale J, Stern AC, Grass P, Mach M, Dierich MP, Huber C: Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: Report of a phase I trial in bone marrow transplant recipients. J Infect Dis 163:1344–1347, 1991.PubMedGoogle Scholar
  196. 194.
    Skarp-Orberg I, Kokeberg I, Olding-Stenkvist E, Tufveson G: Use of human monoclonal anti-cytomegalovirus antibody for the treatment of severe cytomegalovirus after renal transplantation. Transplant Proc 22:234, 1990.PubMedGoogle Scholar
  197. 195.
    Plotkin SA, Friedman HM, Fleisher GR, Dafoe DC, Grossman RA, Smiley ML, Starr SE, Wlodaver C, Friedman AD, Barker CF: Towne-vaccine-induced prevention of cyto-megalovirus disease after renal transplants. Lancet 528–530, 1984.Google Scholar
  198. 196.
    Plotkin SA: Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 265:1383–1385, 1994.PubMedGoogle Scholar
  199. 197.
    McLaughlin B, Taylor E, Tanamache B, Pande H, Li-C-R, Zaia J, Forman SJ, Greenberg PD, Riddell SR: Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific CTL. J Med Virol 43:103–110, 1994.Google Scholar
  200. 198.
    Weiler S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595–605, 1993.Google Scholar
  201. 199.
    Jacobson MA, Gallant J, Wang LH, Coakley D, Weiler S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J: Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 38:1534–1540, 1994.PubMedGoogle Scholar
  202. 200.
    Neyts J, Declercq E: Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochem Pharmacol 47:39–41, 1994.PubMedGoogle Scholar
  203. 201.
    Neyts J, Stals F, Atherton S, Persoons M, Bruggeman C, Declercq E: Efficacy of HPMPC in the treatment of CMV infections in various animal models. In Michelson S, Plotkin S (eds): Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Amsterdam: Elsevier Science, 1993, pp 279–285.Google Scholar
  204. 202.
    Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, Jaffe HS: (S)-1-[3-Hydroxy-2-(Phosphonylmethoxy)propyl]-cytosine (Cidofir): Results of a phase I/II study of a novel nucleotide anlogue. J Infect Dis 171:788–796, 1995.PubMedGoogle Scholar
  205. 203.
    Riddel SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257:238–241, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Michael Boeckh
  • Raleigh Bowden

There are no affiliations available

Personalised recommendations